C4 Therapeutics, Inc. (C4T), a clinical-stage biopharmaceutical company, announced its financial results for the second quarter ended June 30, 2024, along with recent business highlights. The company reported a total revenue of $12.0 million for the quarter, a significant increase from $2.7 million in the same period the previous year, largely due to an $8.0 million milestone payment from Biogen. Research and Development expenses decreased to $23.8 million from $29.9 million in Q2 2023, while General and Administrative expenses also saw a slight decrease. The net loss for the quarter was $17.7 million, or $0.26 per share, improved from a net loss of $35.9 million, or $0.73 per share, in Q2 2023. The company's cash position was reported at $295.7 million, expected to fund operations into 2027. C4T also highlighted progress in its clinical trials, including the ongoing CFT1946 Phase 1 trial in BRAF V600X solid tumors and the cemsidomide Phase 1 trial in multiple myeloma and non-Hodgkin’s lymphoma. Preliminary data from the CFT1946 trial will be presented at the ESMO Congress 2024. The company's leadership expressed confidence in the momentum of their clinical and discovery programs.

C4 Therapeutics, Inc. (C4T), a clinical-stage biopharmaceutical company, announced its financial results for the second quarter ended June 30, 2024, along with recent business highlights. The company reported a total revenue of $12.0 million for the quarter, a significant increase from $2.7 million in the same period the previous year, largely due to an $8.0 million milestone payment from Biogen. Research and Development expenses decreased to $23.8 million from $29.9 million in Q2 2023, while General and Administrative expenses also saw a slight decrease. The net loss for the quarter was $17.7 million, or $0.26 per share, improved from a net loss of $35.9 million, or $0.73 per share, in Q2 2023. The company's cash position was reported at $295.7 million, expected to fund operations into 2027. C4T also highlighted progress in its clinical trials, including the ongoing CFT1946 Phase 1 trial in BRAF V600X solid tumors and the cemsidomide Phase 1 trial in multiple myeloma and non-Hodgkin’s lymphoma. Preliminary data from the CFT1946 trial will be presented at the ESMO Congress 2024. The company's leadership expressed confidence in the momentum of their clinical and discovery programs.